Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes

OBJECTIVE: This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing β-cells in subjects with new-onset type 1 diabetes. RESEARCH DESIGN AND METHODS: A multi-center, randomized, placebo-controlled, double-masked trial was initiate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Peter A., Quinlan, Scott, Krause-Steinrauf, Heidi, Greenbaum, Carla J., Wilson, Darrell M., Rodriguez, Henry, Schatz, Desmond A., Moran, Antoinette M., Lachin, John M., Skyler, Jay S.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845036/
https://www.ncbi.nlm.nih.gov/pubmed/20067954
http://dx.doi.org/10.2337/dc09-1349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845036/
https://www.ncbi.nlm.nih.gov/pubmed/20067954
http://dx.doi.org/10.2337/dc09-1349

Ejemplares similares